Sai Parenterals Limited (SAIPARENT) — Announcement(2 announcements)

· NSE Neutral
1 Announcement Neutral 📄 PDF

Sai Parenterals announced its subsidiary Noumed Pharmaceuticals secured an exclusive OTC medicine supply agreement with Australia's leading pharmacy network valued at AUD 202 million (INR 1300 crores), effective 1 July 2026 for 7.5 years with a possible 3-year extension.

2 Announcement ✨ Positive 📄 PDF

Sai Parenterals announced that its Australian subsidiary Noumed Pharmaceuticals renewed an exclusive OTC supply agreement with major Australian pharmacy chains for 7.5 years, valued at AUD 202 million (INR 1300 crores), expanding recurring revenue and international footprint. The deal locks in predictable income, adds 12 new products annually, and strengthens regulatory and manufacturing capabilities in a key regulated market, enhancing long-term growth potential for the parent company.

About Sai Parenterals Limited (SAIPARENT)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹2,126.13 Cr

View full SAIPARENT stock details →

📡 Get AI alerts when SAIPARENT files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SAIPARENT — Free

📊 More SAIPARENT filings

See all SAIPARENT filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

📡 Get AI alerts when SAIPARENT files new disclosures

Track SAIPARENT filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SAIPARENT — Free

Free account · 2 AI queries/day